<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227899</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10293</org_study_id>
    <nct_id>NCT04227899</nct_id>
  </id_info>
  <brief_title>LIFE-BTK Randomized Controlled Trial</brief_title>
  <acronym>LIFE-BTK</acronym>
  <official_title>LIFE-BTK (pivotaL Investigation of saFety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-market clinical evaluation of the everolimus eluting ESPRIT™ BTK System for the planned
      treatment of narrowed infrapopliteal lesions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">November 25, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Limb Salvage and Primary Patency at 6 Months</measure>
    <time_frame>At 6 months</time_frame>
    <description>It includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death)</measure>
    <time_frame>At 30 days (for POD) and 6 months (for MALE)</time_frame>
    <description>MALE includes above ankle amputation in index limb, major re-intervention at 6 months and POD includes perioperative (30 day) mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Acute Procedure Success</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Successful target lesion treatment is defined as final diameter stenosis &lt; 30% with final number of run-off vessels equivalent to or greater than number of run-off vessels at pre-procedure, with no residual dissection NHLBI grade ≥ type C, and no transient or sustained angiographic complications (e.g. distal embolization, perforation, thrombosis). Achieved using balloons plus ESPRIT BTK in the treatment arm and balloons in the control arm. This is defined on a per lesion basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Device Success</measure>
    <time_frame>During the procedure</time_frame>
    <description>Device success is defined on a per device basis, as the achievement of successful delivery and deployment of the study device(s) at the intended target lesion and successful withdrawal of the delivery catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Technical Success</measure>
    <time_frame>During the procedure</time_frame>
    <description>Technical success is defined on a per lesion basis as the attainment of a final residual stenosis of &lt; 30% at the intended target lesion(s) following use of the study device(s). Standard pre-dilatation catheters and post-dilatation catheters (if applicable) may be used. Bailout at lesion level does not impact technical success if the above criteria are met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Success</measure>
    <time_frame>Within 2 days after the index procedure or at hospital discharge</time_frame>
    <description>Clinical success is defined on a per patient basis, as the attainment of a final residual stenosis of &lt; 30% using the study device(s) and/or any adjunctive device at all intended target lesion(s) without complications within 2 days after the index procedure or at hospital discharge, whichever is sooner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Angiographic acute gain (in-segment)</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Angiographic acute gain (in-device)</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD). Angiographic acute gain (in-device) will be assessed for ESPRIT arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Limb Salvage and Primary Patency</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death)</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>MALE includes above ankle amputation in index limb, major re-interventions at 1 month, 3 months, 6 months, 1 year and annually through 5 years, and POD includes perioperative (30 day) mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Above Ankle Amputation</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Restenosis</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Freedom from re-narrowing of the artery following the alleviation of a previous narrowing. It is defined as the presence of a hemodynamically significant restenosis (≥ 50%), as determined by angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Amputation-free Survival</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All-cause Death</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>All-cause Death composed of cardiac death, vascular death and non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Arterial Thrombosis</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.
Acute thrombosis: 0 - 24 hours post study procedure
Subacute thrombosis: &gt; 24 hours - 30 days post study procedure
Late thrombosis: 31 days - 1 year post-procedure
Very late thrombosis: &gt; 1 year post-procedure Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Major Re-intervention on index limb</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Major Limb Re-interventions includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis &gt; 70% by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion</measure>
    <time_frame>At 1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Wound Assessment for Healing</measure>
    <time_frame>At 14 days, 30 days, 42 days and 90 days</time_frame>
    <description>Wound assessment will be performed to determine whether the wound is improving (i.e. healing), not changing, or worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Wound Assessment for Infection</measure>
    <time_frame>At 14 days, 30 days, 42 days and 90 days</time_frame>
    <description>Wound Assessment for Infection will be performed to determine the clinical indication of the presence or absence of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb</measure>
    <time_frame>At baseline,1 month, 3 months, 6 months, 1 year and annually through 5 years</time_frame>
    <description>The Rutherford Becker scale is a classification system for claudication and limb ischemia.
Categories and Clinical Description:
Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <arm_group>
    <arm_group_label>ESPRIT™ BTK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who receives ESPRIT™ BTK device will be included in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous Transluminal Angioplasty (PTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who receives PTA treatment will be included in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESPRIT™ BTK Device</intervention_name>
    <description>Participants will receive ESPRIT™ BTK Device</description>
    <arm_group_label>ESPRIT™ BTK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty (PTA) Device</intervention_name>
    <description>Participants will receive PTA treatment</description>
    <arm_group_label>Percutaneous Transluminal Angioplasty (PTA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          1. Subject must provide written informed consent prior to any clinical investigation
             related procedure.

          2. Subject has symptomatic Critical Limb Ischemia (CLI), Rutherford Becker Clinical
             Category 4 or 5.

          3. Subject requires primary treatment of up to two de novo or restenotic (treated with
             prior PTA) infrapopliteal lesions

          4. Subject must be at least 18 years of age.

          5. Female subject of childbearing potential should not be pregnant and must be on birth
             control.

        Note: Female subjects of child-bearing potential must have a negative pregnancy test done
        within 7 days prior to the index procedure per site standard test.

        Anatomic Inclusion Criteria:

          1. Up to two native infrapopliteal lesions, each lesion located in separate
             infrapopliteal vessel in the same limb. Restenotic (from prior PTA) lesions are
             allowed.

               1. Lesion must be located in the proximal 2/3 of native infrapopliteal vessels, with
                  vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm by investigator visual assessment.

               2. A total target lesion length of up to 100 mm.

               3. A maximum of 3 scaffolds can be implanted at the target lesion

               4. The total scaffold length among all target lesions must not exceed 170 mm (total
                  everolimus drug dose of 1790 µg).

               5. The target vessel cannot have any other angiographic significant lesions (≥50%).

               6. Tandem lesions are allowed if they are &lt; 3 cm apart and the total length of
                  diseased segment is ≤ 100 mm.

          2. Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the
             procedure. If needed, quantitative imaging (angiography, IVUS, and/or OCT) can be used
             to aid accurate sizing of the vessels.

          3. The distal margin of the target lesion must be located ≥ 10 cm proximal to the
             proximal margin of the ankle mortise. The vessel segment distal to the target lesion
             must be patent all the way to the ankle, with no significant lesion (≥ 50% stenosis).

          4. Significant lesion (≥ 50% stenosis) in the inflow artery(ies) must be treated
             successfully (as per physician's assessment of the angiography) through standard of
             care prior to the treatment of the target lesion. Treatment can be done within the
             same trial procedure

          5. Non-target lesion(s) (if applicable) must be located in separate infrapopliteal
             vessel(s) from the target lesion, and suitable to be treated per institution standard
             of care.

          6. Guidewire must cross the lesion successfully in antegrade fashion.

        Exclusion Criteria:

        General Exclusion Criteria:

          1. Subject is currently participating in another clinical investigation that has not yet
             completed its primary endpoint.

          2. Pregnant or nursing subjects and those who plan pregnancy during the clinical
             investigation follow-up period.

          3. Presence of other anatomic or comorbid conditions, or other medical, social, or
             psychological conditions that, in the investigator's opinion, could limit the
             subject's ability to participate in the clinical investigation or to comply with
             follow-up requirements.

          4. Incapacitated individuals, defined as persons who are mentally ill, mentally
             handicapped, or individuals without legal authority, are excluded from the study
             population.

          5. Subject has had any type of amputation to the ipsilateral extremity, or a
             contralateral extremity amputation other than the toe or forefoot.

          6. Subject has known hypersensitivity or contraindication to device material and its
             degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
             be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
             adequately pre-medicated.

          7. Subject has known allergic reaction, hypersensitivity or contraindication to aspirin;
             or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants
             such as heparin or bivalirudin, and therefore cannot be adequately treated with study
             medications. Subject with planned surgery or procedure necessitating discontinuation
             of antiplatelet medications, within 12 months after index procedure.

          8. Subject has life expectancy ≤ 1 year.

          9. Subject has had a stroke within the previous 3 months with residual Rankin score of ≥
             2.

         10. Subject has renal insufficiency as defined as an estimated GFR &lt; 30 ml/min per 1.73m2.

         11. Subject is currently on dialysis.

         12. Subject with serum albumin &lt; 3 g/dL

         13. Subject has platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC &lt; 3,000
             cells/mm3, or hemoglobin &lt; 9.0 g/dl.

         14. Subject has known serious immunosuppressive disease (e.g., human immunodeficiency
             virus), or has severe autoimmune disease, that requires chronic immunosuppressive
             therapy (e.g., systemic lupus erythematosus, etc.), or subject is receiving
             immunosuppression therapy for other conditions.

         15. Subject has Body Mass Index (BMI) &lt;18.

         16. Subject is receiving or scheduled to receive anticancer therapy for malignancy within
             1 year prior to or after the procedure.

         17. Subject has coagulation disorder.

         18. Subject who requires thrombolysis as a primary treatment modality or requires other
             treatment for acute limb ischemia of the target limb.

         19. Subject has previously had, or requires surgical revascularization involving any
             vessel of the ipsilateral extremity.

         20. Subject has systemic or limb infection, until treated successfully.

         21. Subject is bedridden or unable to walk (with assistance is acceptable).

         22. Subject with extensive tissue loss salvageable only with complex foot reconstruction
             or non-traditional transmetatarsal amputations. This includes subjects with:

               1. Osteomyelitis including and/or proximal to the metatarsal head

               2. Gangrene involving the plantar skin of the forefoot, midfoot, or heel

               3. Deep ulcer or large shallow ulcer (&gt; 3 cm) involving the plantar skin of the
                  forefoot, midfoot, or heel

               4. Full thickness heel ulcer with/without calcaneal involvement

               5. Any wound with calcaneal bone involvement

               6. Wounds that are deemed to be neuropathic or non-ischemic in nature

               7. Wounds that would require flap coverage or complex wound management for large
                  soft tissue defect

               8. Full thickness wounds on the dorsum of the foot with exposed tendon or bone.

         23. Subject is unable or unwilling to provide written consent prior to enrollment

         24. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly
             spreading novel infectious agent within the prior 2 months

        Anatomic Exclusion Criteria:

          1. Retrograde crossing of the guidewire.

          2. Lesions with severe calcification, in which there is a high likelihood that successful
             pre-dilatation cannot be achieved.

          3. Lesion that has prior metallic stent implant.

          4. Significant (-≥ 50% stenosis) lesion in a distal outflow artery that would be perfused
             by the target vessel and that requires treatment at the time of the index procedure.

          5. Inflow lesions or non-target infrapopliteal lesions that were treated using paclitaxel
             coated or eluting stents or DCB, during the index procedure.

          6. Subject has had or will require treatment in any peripheral anatomy vessel with a
             drug-coated or drug-eluting device &lt; 90 days pre-study procedure.

          7. Target or (if applicable) non-target vessel contains visible thrombus as indicated in
             the angiographic images.

          8. Subject has angiographic evidence of thromboembolism or atheroembolism in the
             ipsilateral extremity. (Pre- and post-angiographic imaging must confirm the absence of
             emboli in the distal anatomy.)

          9. Target lesion can only be accessed via retrograde or pedal approach.

         10. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting
             arterial lesions left untreated.

         11. No angiographic evidence of a patent pedal artery.

         12. Target or (if applicable) non-target lesion location requiring bifurcation treatment
             method that requires scaffolding of both branches (provisional treatment, without
             intention of scaffolding both branches is acceptable).

         13. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery
             of the ipsilateral extremity.

         14. Visual assessment of the target lesion suggests that the investigator is unable to
             pre-dilate the lesion according to the vessel diameter.

         15. Target lesion has a high probability that atherectomy will be required at the time of
             index procedure for treatment of the target vessel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon L Varcoe, MBBS, MS, FRACS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Private Hospital, Randwick, NSW, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahil Parikh, MD, FACC, FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian DeRubertis, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles, CA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rhonda Hensley</last_name>
    <phone>+1 (828) 559-0080</phone>
    <email>rhonda.hensley@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine S Ruster, PhD</last_name>
    <phone>+1 (408) 845-0764</phone>
    <email>karine.piard-ruster@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ian Cawich, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Cardiovascular Research Institute</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ashit Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Brian DeRubertis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mahmood Razavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Donald Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80238</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ehrin Armstrong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Carlos Mena-Hurtado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nelson Bernardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manatee Memorial Hospital</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Santosh Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac &amp; Vascular Institute Research Foundation, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christopher Caputo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yazan Khatib, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Andrew Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Rohan Kalathiya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eric Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Craig Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Lawrence Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marc Schermerhorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Heart &amp; Vascular Clinic</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mark Fleming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Richard Kovach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>David Oconnor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>John Rundback</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anvar Babaev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Prakash Krishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Sahil Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>George Adams, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mehdi Shishehbor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>John Corl, MD, FACC, FSCAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gary Ansel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced CardioVascular Solutions</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jim Melton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Antonis Pratsos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Consultants in Cardiovascular Diseases</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Matthew Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Rabih Chaer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anmed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Brent Mc Laurin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thomas Todoran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Chris Metzger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center at Lubbock</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mohammad Ansari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Health Resources Presbyterian Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Vijay Ramanath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeffrey Carr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>David Dexter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular, PLLC</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Brian Ferris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Private Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ramon Varcoe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Vikram Puttaswamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <investigator>
      <last_name>Andrew Holden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi Hospital</name>
      <address>
        <city>New Taipei City</city>
        <state>Xindian</state>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hsuan-Li Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Zhongzheng</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jen-Kuang Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infrapopliteal lesions</keyword>
  <keyword>ESPRIT™ BTK Everolimus Eluting Bioresorbable Scaffold System</keyword>
  <keyword>Percutaneous transluminal angioplasty (PTA)</keyword>
  <keyword>ABT-CIP-10293</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

